All In Biotech

Investigational drug · Phase 3

DW51211

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Bronchitis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

1

Any phase or sponsor naming "DW51211"

First trial start

2024

Mar 28, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "DW51211", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Acute Bronchitis

Largest trials

Live from ClinicalTrials.gov: studies naming "DW51211" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Acute Bronchitis

  • RaphaminMMH-407Phase 35 trials

    Materia Medica Holding · Rhinosinusitis, Rhinosinusitis Acute, Cystitis Chronic

  • AG2001Phase 31 trial

    Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis

  • AG20011Phase 31 trial

    Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis

  • AG20012Phase 31 trial

    Ahn-Gook Pharmaceuticals Co.,Ltd · Acute Bronchitis

  • DW5121Phase 31 trial

    Daewon Pharmaceutical Co., Ltd. · Acute Bronchitis

  • DW51212Phase 31 trial

    Daewon Pharmaceutical Co., Ltd. · Acute Bronchitis

  • YHP2401Phase 31 trial

    Yuhan Corporation · Acute Bronchitis

  • YHR2402Phase 31 trial

    Yuhan Corporation · Acute Bronchitis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.